Peripheral Neuropathic Pain - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Peripheral Neuropathic Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Peripheral Neuropathic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Peripheral Neuropathic Pain Overview 6
Therapeutics Development 7
Pipeline Products for Peripheral Neuropathic Pain - Overview 7
Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis 8
Peripheral Neuropathic Pain - Therapeutics under Development by Companies 9
Peripheral Neuropathic Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Peripheral Neuropathic Pain - Products under Development by Companies 12
Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development 13
Acorda Therapeutics, Inc. 13
Astellas Pharma Inc. 14
Eli Lilly and Company 15
GW Pharmaceuticals plc 16
Nektar Therapeutics 17
Pfizer Inc. 18
Phosphagenics Limited 19
Sunovion Pharmaceuticals Inc. 20
Peripheral Neuropathic Pain - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 29
ASP-8477 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
capsaicin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DSP-2230 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
duloxetine hydrochloride DR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
nabiximols - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NKTR-171 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
oxycodone ER - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
pregabalin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Peripheral Neuropathic Pain - Recent Pipeline Updates 42
Peripheral Neuropathic Pain - Dormant Projects 52
Peripheral Neuropathic Pain - Discontinued Products 53
Peripheral Neuropathic Pain - Product Development Milestones 54
Featured News & Press Releases 54
Mar 14, 2013: European Commission Approves New Pre-treatment Options For NeurogesX's Qutenza In Peripheral Neuropathic Pain 54
Aug 30, 2012: NeurogesX's Partner Astellas Presents Multiple Posters On Qutenza At 14th World Congress On Pain 54
Jul 24, 2012: NeurogesX Partner Astellas Enrolls First Patient In EU Clinical Trial For QUTENZA For Treatment Of Peripheral Neuropathic Pain 55
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 56
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 56
May 21, 2009: NeurogesX Receives European Commission Approval for Qutenza 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Peripheral Neuropathic Pain, H2 2014 7
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Peripheral Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H2 2014 13
Peripheral Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2014 14
Peripheral Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2014 15
Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals plc, H2 2014 16
Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2014 17
Peripheral Neuropathic Pain - Pipeline by Pfizer Inc., H2 2014 18
Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2014 19
Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 28
Peripheral Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2014 42
Peripheral Neuropathic Pain - Dormant Projects, H2 2014 52
Peripheral Neuropathic Pain - Discontinued Products, H2 2014 53